CRSP
Price
$38.04
Change
+$1.09 (+2.95%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
3.29B
68 days until earnings call
NTLA
Price
$7.69
Change
+$0.53 (+7.40%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
796.56M
58 days until earnings call
Interact to see
Advertisement

CRSP vs NTLA

Header iconCRSP vs NTLA Comparison
Open Charts CRSP vs NTLABanner chart's image
CRISPR Therapeutics AG
Price$38.04
Change+$1.09 (+2.95%)
Volume$30.44K
Capitalization3.29B
Intellia Therapeutics
Price$7.69
Change+$0.53 (+7.40%)
Volume$108.25K
Capitalization796.56M
CRSP vs NTLA Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. NTLA commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and NTLA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (CRSP: $38.04 vs. NTLA: $7.16)
Brand notoriety: CRSP and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 83% vs. NTLA: 184%
Market capitalization -- CRSP: $3.29B vs. NTLA: $796.56M
CRSP [@Biotechnology] is valued at $3.29B. NTLA’s [@Biotechnology] market capitalization is $796.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $321.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 4 bearish.
  • NTLA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а +1.25% price change this week, while NTLA (@Biotechnology) price change was -21.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.76%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was +0.74%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

NTLA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+5.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($3.29B) has a higher market cap than NTLA($797M). CRSP YTD gains are higher at: -3.354 vs. NTLA (-38.593). CRSP has higher annual earnings (EBITDA): -455.24M vs. NTLA (-530.8M). CRSP has more cash in the bank: 1.86B vs. NTLA (504M). NTLA has less debt than CRSP: NTLA (119M) vs CRSP (219M). NTLA has higher revenues than CRSP: NTLA (45.6M) vs CRSP (35M).
CRSPNTLACRSP / NTLA
Capitalization3.29B797M412%
EBITDA-455.24M-530.8M86%
Gain YTD-3.354-38.5939%
P/E RatioN/AN/A-
Revenue35M45.6M77%
Total Cash1.86B504M368%
Total Debt219M119M184%
FUNDAMENTALS RATINGS
CRSP vs NTLA: Fundamental Ratings
CRSP
NTLA
OUTLOOK RATING
1..100
63
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8394
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (23) in the Biotechnology industry is somewhat better than the same rating for CRSP (65). This means that NTLA’s stock grew somewhat faster than CRSP’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that NTLA’s stock grew similarly to CRSP’s over the last 12 months.

NTLA's SMR Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that NTLA’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's Price Growth Rating (83) in the Biotechnology industry is in the same range as NTLA (94). This means that CRSP’s stock grew similarly to NTLA’s over the last 12 months.

CRSP's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that CRSP’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPNTLA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 19 days ago
80%
Bullish Trend 7 days ago
77%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USLCX43.79N/A
N/A
JHancock U.S. Global Leaders Growth C
WSEFX34.69N/A
N/A
Boston Trust Walden Equity
WPCSX46.82N/A
N/A
AB Concentrated Growth C
TRZRX14.93N/A
N/A
T. Rowe Price Real Assets Z
BAILX12.03N/A
N/A
Brown Advisory Sustainable Intl Ldrs Ins